Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 4, 2009, Pages 387-393

  McConn II, D J ^a,b   Lin, Y S ^a   Mathisen, T L ^c   Blough, D K ^a   Xu, Y ^a,d   Hashizume, T ^a,e   Taylor, S L ^a,f   Thummel, K E ^a   Shuhart, M C ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b THERAVANCE INC   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f CARIS LIFE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DRUG METABOLIZING ENZYME; MIDAZOLAM;

ADULT; ARTICLE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG HYDROXYLATION; DRUG METABOLISM; DUODENUM; DUODENUM BIOPSY; DUODENUM MUCOSA; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CATALYSIS; CYTOCHROME P-450 CYP3A; DUODENUM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTESTINAL MUCOSA; LIVER CIRRHOSIS; MALE; MIDAZOLAM; MIDDLE AGED;

EID: 62649125644     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.292     Document Type: Article

References (36)

1. Morgan, D.J. & McLean, A.J. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin. Pharmacokinet. 29, 370-391 (1995).
2. Rodighiero, V. Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinet. 37, 399-431 (1999).
3. Lamba, J.K., Lin, Y.S., Schuetz, E.G. & Thummel, K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54, 1271-1294 (2002).
4. George, J., Liddle, C., Murray, M., Byth, K. & Farrell, G.C. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem. Pharmacol. 49, 873-881 (1995).
5. Guengerich, F.P. & Turvy, C.G. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 256, 1189-1194 (1991).
6. Lown, K., Kolars, J., Turgeon, K., Merion, R., Wrighton, S.A. & Watkins, P.B. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin. Pharmacol. Ther. 51, 229-238 (1992).
7. MacGilchrist, A.J. et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 27, 190-195 (1986).
8. Kleinbloesem, C.H., van Harten, J., Wilson, J.P., Danhof, M., van Brummelen, P. & Breimer, D.D. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin. Pharmacol. Ther. 40, 21-28 (1986).
9. van Harten, J., van Brummelen, P., Wilson, J.H., Lodewijks, M.T. & Breimer, D.D. Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. Eur. J. Clin. Pharmacol. 34, 387-394 (1988).
10. Somogyi, A., Albrecht, M., Kliems, G., Schafer, K. & Eichelbaum, M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br. J. Clin. Pharmacol. 12, 51-60 (1981).
11. Pentikainen, P.J., Valisalmi, L., Himberg, J.J. & Crevoisier, C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J. Clin. Pharmacol. 29, 272-277 (1989).
12. Shen, D.D., Kunze, K.L. & Thummel, K.E. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 27, 99-127 (1997).
13. Rostami-Hodjegan, A. & Tucker, G.T. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 35, 1549-1550; reply,1550-1551 (2002).
14. Chalasani, N., Gorski, J.C., Patel, N.H., Hall, S.D. & Galinsky, R.E. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 34, 1103-1108 (2001).
15. Regårdh, C.G., Edgar, B., Olsson, R., Kendall, M., Collste, P. & Shansky, C. Pharmacokinetics of felodipine in patients with liver disease. Eur. J. Clin. Pharmacol. 36, 473-479 (1989).
16. Cotting, J., Reichen, J., Kutz, K., Laplanche, R. & Nuesch, E. Pharmacokinetics of isradipine in patients with chronic liver disease. Eur. J. Clin. Pharmacol. 38, 599-603 (1990).
17. Robin, D.W., Lee, M., Hasan, S.S. & Wood, A.J. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 54, 630-637 (1993).
18. Lown, K.S. et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test [published erratum appears in Drug Metab. Dispos. 23, ii (1995)]. Drug Metab. Dispos. 22, 947-955 (1994).
19. Lindell, M., Karlsson, M.O., Lennernas, H., Pahlman, L. & Lang, M.A. Variable expression of CYP and Pgp genes in the human small intestine. Eur. J. Clin. Invest. 33, 493-499 (2003).
20. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E. & Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34, 880-886 (2006).
21. Paine, M.F. et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552-1562 (1997).
22. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
23. Garcia-Valdecasas-Campelo, E. et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol. 41, 261-266 (2006).
24. Bouillon, R., Auwerx, J., Dekeyser, L., Fevery, J., Lissens, W. & De Moor, P. Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis. J. Clin. Endocrinol. Metab. 59, 86-89 (1984).
25. Monegal, A. et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif. Tissue Int. 60, 148-154 (1997).
26. Elizondo, G. & Medina-Díaz, I.M. Induction of CYP3A4 by 1[alpha],25-dyhydroxyvitamin D3 in HepG2 cells. Life Sci. 73, 141-149 (2003).
27. Jurutka, P.W. et al. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. J. Cell. Biochem. 94, 917-943 (2005).
28. Thummel, K.E. et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol. Pharmacol. 60, 1399-1406 (2001).
29. Xu, Y. et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1{alpha},25-dihydroxyvitamin D3: implications for drug-induced osteomalacia. Mol. Pharmacol. 69, 56-65 (2006).
30. Xu, Y., Iwanaga, K., Zhou, C., Cheesman, M.J., Farin, F. & Thummel, K.E. Selective induction of intestinal CYP3A23 by 1alpha,25-dihydroxyvitamin D3 in rats. Biochem. Pharmacol. 72, 385-392 (2006).
31. Makishima, M. et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313-1316 (2002).
32. Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646-649 (1973).
33. Bonkovsky, H.L., Hauri, H.P., Marti, U., Gasser, R. & Meyer, U.A. Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology 88, 458-467 (1985).
34. Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
35. Lin, Y.S. et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62, 162-172 (2002).
36. Kharasch, E.D. & Thummel, K.E. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth. Analg. 76, 1033-1039 (1993).